Immune-Onc Therapeutics
Feng Deng is a director at Immune-Onc Therapeutics. Feng has over 25 years of experience in the technology industry. Feng started their career as a Sr Design Engineer at Intel Corp in 1993. Feng then spent 7 years as the Chief Strategy Officer and VP of Engineering at NetScreen Technologies. In 2004, Feng joined Juniper Networks as the VP of Strategy and Corp Dev. Feng left Juniper in 2005 to join Immune-Onc Therapeutics.
Feng Deng has an MBA in finance from The Wharton School and MS degrees in computer engineering and electronic engineering from the University of Southern California and Tsinghua University, respectively.
This person is not in the org chart
This person is not in any offices
Immune-Onc Therapeutics
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.